Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Lattice corneal dystrophy Indication Strategy Report 2026: TGFBI, Trials and Deals
3 August 2026
2026 Lattice corneal dystrophy indication strategy covering epidemiology, TGFBI biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Granular corneal dystrophy Indication Strategy Report 2026: TGFBI, Trials and Deals
3 August 2026
2026 Granular corneal dystrophy indication strategy covering epidemiology, TGFBI biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Congenital hereditary endothelial dystrophy Indication Strategy Report 2026: SLC4A11, Trials and Deals
3 August 2026
2026 Congenital hereditary endothelial dystrophy indication strategy covering epidemiology, SLC4A11 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Posterior polymorphous corneal dystrophy Indication Strategy Report 2026: ZEB1, Trials and Deals
3 August 2026
2026 Posterior polymorphous corneal dystrophy indication strategy covering epidemiology, ZEB1 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Hereditary sensory retinal dystrophy Indication Strategy Report 2026: ABCA4, Trials and Deals
3 August 2026
2026 Hereditary sensory retinal dystrophy indication strategy covering epidemiology, ABCA4 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Schnyder corneal dystrophy Indication Strategy Report 2026: UBIAD1, Trials and Deals
3 August 2026
2026 Schnyder corneal dystrophy indication strategy covering epidemiology, UBIAD1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Neurotrophic keratitis stage 3 Indication Strategy Report 2026: NGF, Trials and Deals
3 August 2026
2026 Neurotrophic keratitis stage 3 indication strategy covering epidemiology, NGF biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Aniridia-associated keratopathy Indication Strategy Report 2026: PAX6, Trials and Deals
3 August 2026
2026 Aniridia-associated keratopathy indication strategy covering epidemiology, PAX6 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Keratoconus progressive Indication Strategy Report 2026: LOX, Trials and Deals
3 August 2026
2026 Keratoconus progressive indication strategy covering epidemiology, LOX biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Wolfram syndrome optic atrophy Indication Strategy Report 2026: WFS1, Trials and Deals
3 August 2026
2026 Wolfram syndrome optic atrophy indication strategy covering epidemiology, WFS1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Autosomal dominant optic atrophy Indication Strategy Report 2026: OPA1, Trials and Deals
3 August 2026
2026 Autosomal dominant optic atrophy indication strategy covering epidemiology, OPA1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Choroidal osteoma Indication Strategy Report 2026: RANKL, Trials and Deals
3 August 2026
2026 Choroidal osteoma indication strategy covering epidemiology, RANKL biology, active trials, transactions, unmet need, competition and market attractiveness.